BioAge Labs initiated dosing in its Phase 2 trial (QUELL-DME) for BGE-102, an oral NLRP3 inhibitor aimed at treating diabetic macular edema, with topline results expected in late 2027. The company also completed enrollment in a Phase 2 cardiovascular trial (QUELL-CV) for BGE-102 in obese adults, with data anticipated by the end of 2026. Additionally, BioAge is advancing its APJ agonist program for obesity, targeting IND submission by year-end 2026. Financially, BioAge reported a net loss of $33.5 million in Q3 2026 but holds $352.3 million in cash and securities, supporting operations through 2029.
BioAge Labs' Q3 2026 financial results and business updates provide context for readers interested in recent biotech developments. For readers following the health sector, here is Pluang's market snapshot as of Nov 06, 2026 04:11 WIB: out of 150 priced health-sector US stocks tradable on Pluang, 16 rose and 134 fell today. Notable movers include TXG (10X Genomics Inc) at USD 56.99 with a 1-day change of -15.60%, TWST (Twist Bioscience Corp) at USD 120.79 down 15.28%, and DNA (Ginkgo Bioworks Holdings Inc) at USD 9.90 down 15.02%, with TXG showing a typical hold time on Pluang of 92 days and a Pluang order activity of 88% sell versus 12% buy.
Grupo Aeroportuario del Sureste (ASUR) reported a 0.9% decrease in total passenger traffic for October 2026 compared to the previous year, totaling 9.3 million passengers. While Colombia, Puerto Rico, Brazil, and Ecuador saw modest increases in domes...
Vaalco Energy announced a quarterly cash dividend of $0.0625 per share for Q4 2026, payable on December 22, 2026, to shareholders of record as of November 20, 2026. This marks the company's 20th consecutive quarterly dividend, reflecting its strong c...
Mercer International reported a significant improvement in its third quarter 2026 Operating EBITDA, narrowing losses to negative $2.9 million from negative $28.1 million a year earlier, driven by cost savings and government grants. The company has en...
Ameren Corporation reported third quarter 2026 GAAP diluted EPS of $2.42, up from $2.35 in 2025, driven by infrastructure investments and higher electric sales. The company raised its 2026 earnings guidance to $5.35-$5.55 per share and set 2027 guida...
Micron Technology announced that board member Linnie M. Haynesworth will retire at the annual shareholders meeting on January 14, 2027. Haynesworth has served on the board since 2021, contributing over 30 years of technology expertise, especially in ...
